


 <p><b>INFORMATION DISCLOSURE CITATION</b> (See several sheets if necessary)</p>				ATTY DOCKET NO. <b>022438.43867</b>		APPLICATION NO. <b>09/965.738</b>		
				APPLICANT(S) <b>O'Brien, et al.</b>				
				FILING DATE <b>September 27, 2001</b>		GROUP ART UNIT <b>1642</b>		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<b>GW</b>	AA	WO 00/36107	06/22/00	World	C12N 15/12	C07K 14/47	✓	
<b>GW</b>	BB	0 288 082	10/26/88	Europe	C07K 15/14	C12P 21/00	✓	
<b>GW</b>	CC	WO 02/092836	11/21/02	World	C12Q		✓	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
<b>GW</b>	DD	"More than 15 years of CA125: What is known about the antigen, its structure and its function" T.J. O'Brien, et al. The International Journal of Biological Markers, Vol. 13, no. 4, pp. 188-195						
<b>GW</b>	EE	"Isolation and Characterization of Ovarian Cancer Antigen CA125 Using a New Monoclonal Antibody (VK-8): Identification as a Mucin-type Molecule" Kenneth O. Lloyd, et al. Int. J. Cancer: 71, 842-850 (1997)						
EXAMINER <b>Gangsonickal</b>				DATE CONSIDERED <b>2/7/06</b>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

 <p><b>OIPF INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)</p>		Docket Number (Optional) <b>022438.43867</b>	Application Number <b>09/965,738</b>
		Applicant(s) <b>O'Brien, et al.</b>	
		Filing Date <b>September 27, 2001</b>	Group Art Unit <b>1642</b>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
FF	FF	<p>"Immunohistochemical Characterization of 22 Monoclonal Antibodies against the CA125 Antigen 2nd Report from the ISOBM TD-1 Workshop" M. Nap, et al. Tumor Biol. 1996: 17: 325-331</p>	
GG	GG	<p>"Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat" Jean-Luc Desseyn, et al. The Journal of Biological Chemistry, Vol. 272, No. 6, Issue of February 7, pp. 3168-3178 (1997)</p>	
HH	HH	<p>"Isolation of the Murine Nbr1 Gene Adjacent to the Murine Brcal Gene" Julie Chambers, et al. Genomics 38, 305-313 (1996)</p>	
II	II	<p><a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=2566012">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;val=2566012</a> "Nucleotide" Lee Helman, M.D., et al. NCBI Sequence Viewer</p>	
JJ	JJ	<p>"Molecular Cloning of the CA125 Ovarian Cancer Antigen" Beatrice W.T. Yin, et al. The Journal of Biological Chemistry, Vol. 276, No. 29, Issue of July 20, pp. 27371-27375 (2001)</p>	
KK	KK	<p>"The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" Timothy J. O'Brien, et al. Tumor Biol. 2001; 22: 348-366</p>	
LL	LL	<p>"The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure" Timothy J. O'Brien, et al. Tumor Biol 2002; 23: 154-169</p>	
EXAMINER 		DATE CONSIDERED <b>2/7/06</b>	
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>			



Docket Number (Optional) <b>022438.43867</b>		Application Number <b>09/965,738</b>
Applicant(s) <b>O'Brien, et al.</b>		
Filing Date <b>September 27, 2001</b>		Group Art Unit

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GW	CC	10/715,066	11/17/03	O'Brien, et al.			11/17/03
GW	DD	10/475,117	10/16/03	O'Brien, et al.			10/16/03


**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER <i>Gary Michel</i>	DATE CONSIDERED <i>2/7/06</i>
--------------------------------	----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

022438.43867

Application Number

09/965,738

Applicant(s)

O'Brien, et al.

Filing Date

September 27, 2001

Group Art Unit

1642

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA

O'Brien, et al.  
"The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" *Tumor Biology*, Vol. 22, 2001 pp. 348-366 *Duplicate*

BB

Argueso, et al.  
"MUC16 Mucin is Expressed by the Human Ocular Surface Epithelia and Carries the H185 Carbohydrate Epitope" *Invest Ophthalmol Vis Sci* 2003 Jun;44(6):2487-95



EXAMINER

*Gary B. Nichol*

DATE CONSIDERED

*2/7/06*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				Docket Number (Optional) <b>022438.43865</b>		Application Number <b>09/965,738</b>		
				Applicant(s) <b>Timothy J. O'Brien</b>				
				Filing Date <b>9/27/01</b>		Group Art Unit <b>1642</b>		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
GN	AA	6,335,194	1-1-2002	Bennett et al.	435/375		2-2-2000	
GN	BB	6,451,602	9-17-2002	Popoff et al.	435/375		3-2-2000	
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)								
EXAMINER				DATE CONSIDERED				
				<b>2-7-06</b>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	09/965,738
<b>Filing Date</b>	September 27, 2001
<b>First Named Inventor</b>	O'Brien, Timothy J.
<b>Group Art Unit</b>	Unassigned
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	40715-260477
<b>Express Mail Certificate</b>	EV 032 104 775 US

**U.S. PATENT DOCUMENTS**

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449APTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
GW	1	BAST RC et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, <i>N Engl J Med.</i> 309:883-887 (1983)	✓
GW	2	BON GC et al., Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values, <i>Am J Obstet. Gynecol.</i> 174:107-114 (1996)	✓
GW	3	CLEMONS-MILLER, A et al. Intrathecal Cytotoxic T-Cell Immunotherapy for Metastatic Leptomeningeal Melanoma. <i>Clinical Cancer Research</i> 7:917s-924s, March 2001 (Suppl.)	✓
Duplicate	4	DESSEYN JL et al., Human mucin gene MUC5B, the 10.7-kb large central exon encodes various alternate subdomains resulting in a super-repeat. Structural evidence for a 11p15.5 gene family, <i>J Biol. Chem.</i> 272(6):3168-3178 (1997)	✓
GW	5	FENDRICK, JL et al. Characterization of CA 125 Synthesized by the Human Epithelial Amnion WISH Cell Line. <i>Tumor Biol</i> 1993; 14:310-318	✓
	6	FENDRICK, JL et al. CA125 Phosphorylation Is Associated with Its Secretion from the WISH Human Amnion Cell Line. <i>Tumor Biol</i> 1997; 18:278-289	✓
	7	FOON, KA et al., Are solid tumor anti-idotype vaccines ready for prime time?, <i>Clinical Cancer Research</i> 7:1112-1115 (2001)	✓
	8	GENDLER SJ et al., Epithelial mucin genes, <i>Annu. Rev. Physiol.</i> 57:607-634 (1995)	✓
	9	GUM Jr., JR, Mucin genes and the proteins they encode: Structure, diversity and regulation, <i>Am J Respir. Cell Mol. Biol.</i> 7:557-564 (1992)	✓
	10	GUM JR, Human Mucin Glycoproteins: Varied Structures Predict Diverse Properties and Specific Functions. <i>Biochemical Society Transactions.</i> 23(4):795-799, 1995.	✓
	11	HARDARDOTTIR H et al., Distribution of CA125 in embryonic tissue and adult derivatives of the fetal periderm, <i>Am J Obstet. Gynecol.</i> 163;6(1):1925-1931 (1990)	✓
	12	KONISHI I et al., Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line, <i>J Soc. Gynecol. Invest.</i> 1:89-96 (1994)	✓
	13	LLOYD KO et al., Synthesis and secretion of the ovarian cancer antigen CA125 by the human cancer cell line NIH: OVCAR-3, <i>Tumor Biology</i> 22, 77-82 (2001)	
	14	LLOYD KO et al., Isolation and characterization of ovarian cancer antigen CA125 using a new monoclonal antibody (VK-8). Identification as a ucin-type molecule, <i>Int. J. Cancer</i> , 71:842-850 (1997) — Duplicate	✓
GW	15	MARSHALL E, DNA Sequencing: Genome teams adjust to shotgun marriage, <i>Science</i> 292:1982-1983 (2001)	✓
	16	NAP M et al., Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2 <sup>nd</sup> report from the ISOBM TD-1 workshop, <i>Tumor Biology</i> 17:325-331 (1996) Duplicate	✓
GW	17	NUSTAD K et al., CA125 - epitopes and molecular size, <i>Int. J of Biolog. Markers</i> , 13(4)196-199 (1998)	✓

Substitute for form 1449APTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	09/965,738
Filing Date	September 27, 2001
First Named Inventor	O'Brien, Timothy J.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	40715-260477

W	18	NUSTAD K et al., Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: First report from the ISOBM TD-1 workshop <i>Tumor Biology</i> 17:196-219 (1996)	✓
	19	O'BRIEN, TJ et al. CA 125 Antigen in Human Amniotic Fluid and Fetal Membranes. <i>Am J Obstet Gynecol</i> 155:50-55 July, 1986	✓
	20	O'BRIEN, TJ et al. New Monoclonal Antibodies Identify the Glycoprotein Carrying the CA 125 Epitope. <i>Am J Obstet Gynecol</i> 1991; 165:1857-64	✓
	21	O'BRIEN, TJ et al. More Than 15 Years of CA 125: What Is Known about the Antigen, Its Structure and Its Function. <i>The International Journal of Biological Markers</i> 13:188-195 (1998) — Duplicate —	✓
W	22	QUIRK, JR et al. CA 125 in Tissues and Amniotic Fluid During Pregnancy. <i>Am J Obstet Gynecol</i> 159:655-649 (1988)	✓
	23	SANTIN, AD et al. Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics &amp; Gynecology</i> 2000; 96:422-30	✓
	24	SANTIN, AD et al. In vitro Induction of Tumor-Specific Human Lymphocyte Antigen Class I-Restricted CD8+ Cytotoxic T Lymphocytes by Ovarian Tumor Antigen-Pulsed Autologous Dendritic Cells from Patients with Advanced Ovarian Cancer. <i>Am J Obstet Gynecol</i> 2000; 183:601-9	✓
	25	SHIGESMASA, K, et al. p21: a Monitor of p53 Dysfunction in Ovarian Neoplasia. <i>International Journal of Gynecologic Cancer</i> 7:296-303, 1997.	✓
	26	SHIGESMASA, K, et al. p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma. <i>J Soc Gynecol Invest</i> 4:95-102, 1997.	✓
	27	VERMA M et al., Mucin genes: Structure, expression and regulation, <i>Glycoconjugate J.</i> 11:172-179 (1994)	✓
	27	WAGNER, U. et al. Immunological Responses to the Tumor-Associated Antigen CA125 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-Idiotypic Vaccine ACA125. <i>HYBRIDOMA</i> 16:33-40 (1997)	✓
	29	WAGNER U et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotypic antibody ACA125: Immune responses and survival in palliative treatment, <i>Clin. Cancer Res.</i> 7:1112-1115 (2001)	✓
	30	WILLIAMS, SJ et al. MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells. <i>The Journal of Biological Chemistry</i> 276(21):18327-18336, 2001.	✓
	31	YIN TWT et al., Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16), <i>J Biol. Chem.</i> 276:27371-27375 (2001)	✓
	32	ZURAWSKI VR et al., Tissue distribution and characteristics of the CA125 antigen, <i>Cancer Rev.</i> 11-12:102-118 (1998)	✓

Examiner Signature	<i>Timothy J. O'Brien</i>	Date Considered	2/7/06
--------------------	---------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 911366